1. Magnaval JF, Glickman LT, Dorchies P, Morassin B. Highlights of human toxocariasis. Korean J Parasitol. 2001; 39:1–11.
2. Park HY, Lee SU, Huh S, Kong Y, Magnaval JF. A seroepidemiological survey for toxocariasis in apparently healthy residents in Gangwon-do, Korea. Korean J Parasitol. 2002; 40:113–117.
3. Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev. 2003; 16:265–272.
4. Choi D, Lim JH, Choi DC, Paik SW, Kim SH, Huh S. Toxocariasis and ingestion of raw cow liver in patients with eosinophilia. Korean J Parasitol. 2008; 46:139–143.
5. Gavignet B, Piarroux R, Aubin F, Millon L, Humbert P. Cutaneous manifestations of human toxocariasis. J Am Acad Dermatol. 2008; 59:1031–1042.
6. Humbert P, Niezborala M, Salembier R, Aubin F, Piarroux R, Buchet S, Barale T. Skin manifestations associated with toxocariasis: a case-control study. Dermatology. 2000; 201:230–234.
7. Yoshikawa M. Duration of treatment with albendazole for hepatic toxocariasis. Nat Clin Pract Gastroenterol Hepatol. 2009; 6:E1–E2.
8. Stürchler D, Schubarth P, Gualzata M, Gottstein B, Oettli A. Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Ann Trop Med Parasitol. 1989; 83:473–478.
9. Takamatsu K, Sumitani M, Nanjyou S, Nishijima M, Syoji S, Takifuji N, Kiyota H, Daga H, Takeda K. Case of Toxocara canis larva migrans cured by additional treatment with albendazole. Nihon Kokyuki Gakkai Zasshi. 2008; 46:836–841.